These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16483772)

  • 1. Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors.
    Waterson AG; Stevens KL; Reno MJ; Zhang YM; Boros EE; Bouvier F; Rastagar A; Uehling DE; Dickerson SH; Reep B; McDonald OB; Wood ER; Rusnak DW; Alligood KJ; Rudolph SK
    Bioorg Med Chem Lett; 2006 May; 16(9):2419-22. PubMed ID: 16483772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
    Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors.
    Suzuki N; Shiota T; Watanabe F; Haga N; Murashi T; Ohara T; Matsuo K; Oomori N; Yari H; Dohi K; Inoue M; Iguchi M; Sentou J; Wada T
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1601-6. PubMed ID: 21334203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
    Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ
    Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors.
    Waterson AG; Petrov KG; Hornberger KR; Hubbard RD; Sammond DM; Smith SC; Dickson HD; Caferro TR; Hinkle KW; Stevens KL; Dickerson SH; Rusnak DW; Spehar GM; Wood ER; Griffin RJ; Uehling DE
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1332-6. PubMed ID: 19208477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines.
    Hubbard RD; Dickerson SH; Emerson HK; Griffin RJ; Reno MJ; Hornberger KR; Rusnak DW; Wood ER; Uehling DE; Waterson AG
    Bioorg Med Chem Lett; 2008 Nov; 18(21):5738-40. PubMed ID: 18842405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.
    Rheault TR; Caferro TR; Dickerson SH; Donaldson KH; Gaul MD; Goetz AS; Mullin RJ; McDonald OB; Petrov KG; Rusnak DW; Shewchuk LM; Spehar GM; Truesdale AT; Vanderwall DE; Wood ER; Uehling DE
    Bioorg Med Chem Lett; 2009 Feb; 19(3):817-20. PubMed ID: 19111461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
    Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
    J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors.
    Xu G; Abad MC; Connolly PJ; Neeper MP; Struble GT; Springer BA; Emanuel SL; Pandey N; Gruninger RH; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4615-9. PubMed ID: 18653333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.
    Tsou HR; Overbeek-Klumpers EG; Hallett WA; Reich MF; Floyd MB; Johnson BD; Michalak RS; Nilakantan R; Discafani C; Golas J; Rabindran SK; Shen R; Shi X; Wang YF; Upeslacis J; Wissner A
    J Med Chem; 2005 Feb; 48(4):1107-31. PubMed ID: 15715478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
    Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.
    Mastalerz H; Chang M; Gavai A; Johnson W; Langley D; Lee FY; Marathe P; Mathur A; Oppenheimer S; Tarrant J; Tokarski JS; Vite GD; Vyas DM; Wong H; Wong TW; Zhang H; Zhang G
    Bioorg Med Chem Lett; 2007 May; 17(10):2828-33. PubMed ID: 17368025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
    Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
    Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases.
    Suzuki N; Shiota T; Watanabe F; Haga N; Murashi T; Ohara T; Matsuo K; Omori N; Yari H; Dohi K; Inoue M; Iguchi M; Sentou J; Wada T
    Bioorg Med Chem Lett; 2012 Jan; 22(1):456-60. PubMed ID: 22101132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
    Klutchko SR; Zhou H; Winters RT; Tran TP; Bridges AJ; Althaus IW; Amato DM; Elliott WL; Ellis PA; Meade MA; Roberts BJ; Fry DW; Gonzales AJ; Harvey PJ; Nelson JM; Sherwood V; Han HK; Pace G; Smaill JB; Denny WA; Showalter HD
    J Med Chem; 2006 Feb; 49(4):1475-85. PubMed ID: 16480284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New dual inhibitors of EGFR and HER2 protein tyrosine kinases.
    Fink BE; Vite GD; Mastalerz H; Kadow JF; Kim SH; Leavitt KJ; Du K; Crews D; Mitt T; Wong TW; Hunt JT; Vyas DM; Tokarski JS
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4774-9. PubMed ID: 16111887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors.
    Ducray R; Ballard P; Barlaam BC; Hickinson MD; Kettle JG; Ogilvie DJ; Trigwell CB
    Bioorg Med Chem Lett; 2008 Feb; 18(3):959-62. PubMed ID: 18182285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of 1-(2-chloro-2-phenylethyl)-6-methylthio-1H-pyrazolo[3,4-d]pyrimidines 4-amino substituted and their biological evaluation.
    Schenone S; Bruno O; Bondavalli F; Ranise A; Mosti L; Menozzi G; Fossa P; Manetti F; Morbidelli L; Trincavelli L; Martini C; Lucacchini A
    Eur J Med Chem; 2004 Feb; 39(2):153-60. PubMed ID: 14987824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.